In July 2025, Dr. Holger Engel was appointed as CEO of Allergios to realign the company’s development efforts and prepare the platform for clinical applicability. The objective is clear: develop a robust, automatable version of the GranulEye® prototype to enable functional, cell-based allergy diagnostics in routine clinical settings.
Since then, several important steps have been initiated:
- Recruitment of key staff in engineering and software development
- Definition of the technical roadmap for Prototype Version 2.0
- Preparatory work to start lab operations for the next phase, as well as engineering and AI-based image analysis development
The current focus lies in building a reliable, label-free Basophil Activation Test with minimal manual intervention, designed for integration into routine laboratory workflows and towards point-of-care.
This development phase includes both technical refinement and practical testing with clinical samples.
Further updates on the technical development, clinical context, and platform use cases will follow in the coming months.
For now, the focus remains on structured execution.